Arecor Therapeutics (LON:AREC – Get Free Report) released its quarterly earnings results on Thursday. The company reported GBX (8) earnings per share for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a return on equity of 14.26% and a net margin of 38.74%.
Arecor Therapeutics Trading Up 3.4%
AREC stock opened at GBX 75 on Thursday. The company’s 50-day simple moving average is GBX 71.57 and its 200 day simple moving average is GBX 67.96. Arecor Therapeutics has a 52 week low of GBX 56 and a 52 week high of GBX 95. The company has a market capitalization of £28.32 million, a PE ratio of 37.50 and a beta of -0.18. The company has a debt-to-equity ratio of 1.52, a quick ratio of 6.24 and a current ratio of 4.35.
About Arecor Therapeutics
Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.
Further Reading
- Five stocks we like better than Arecor Therapeutics
- Cleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach
- L3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock
- Boeing’s Fighter Victory Opens the Door to Decades of Defense Revenue
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
